Investigational drug · Phase 2
YMI024
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Coronary Artery Disease.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "YMI024"
First trial start
2026
Sep 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "YMI024", any sponsor or status.
Conditions studied
As listed on its trial records.
- Coronary Artery Disease
Approved drugs for the same conditions: Coronary artery disease and heart attack
Largest trials
Live from ClinicalTrials.gov: studies naming "YMI024" as an intervention, largest first.
- Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRPPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07830719 · 180 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 15, 2027
Drug: YMI024; Placebo · For: Coronary Artery Disease
Sites: Fairhope, Alabama; Foley, Alabama; Los Angeles, California · 23 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Coronary Artery Disease
- ObicetrapibPhase 37 trials
NewAmsterdam Pharma · Lipidemia, Preclinical Alzheimer's Disease, Antioxidant Absorption
- ZiltivekimabPhase 34 trials
Novo Nordisk · Acute Myocardial Infarction (AMI), Myocardial Infarction, Heart Failure
- ezetimibe FDCPhase 32 trials
NewAmsterdam Pharma · Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
- YN001Phase 22 trials
Beijing Inno Medicine Co., Ltd. · Atherosclerosis, Coronary Artery Disease, Atherosclerotic Cardiovascular Disease
- HeXell-2020Phase 21 trial
Hexun Biosciences Co., LTD. · Coronary Artery Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.